Revenue qualityDanger
매출 흑자인데 영업CF 적자 (OCF/매출 -51%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.
HEM Pharma
376270 · KOSDAQ₩38,800+1.70%
2026-09-04 closeHEM Pharma last closed at ₩38,800 (+1.70%) on 2026-09-04. Listed on KOSDAQ; price, financials and dividends update daily after market close.
Loading chart…
Close
No active signal.
New high + volume — the real recordrecord · not a prediction
Last 30 sessions
303 picks
Next-day win rate
50.7%
Avg next-day
-0.11%
vs market
-0.49%p
Every new-high-plus-volume pick we actually published (Korea market) — not this stock alone.
Trade plan
Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.
A calculator · not advice or a guarantee
Financials & valuation at a glance
Past reported results · not investment advice
More — deeper indicators
Financial safety
Reference indicatorAs of 2024Distress zoneFinancial-metric reference signal
Altman Z'' zoneZ'' -1.97
Distress
Grey
Safe
- Altman Z''
- -1.97
- Beneish M-Score
- —
- Sloan accrual
- 0.09%
Statistical flag unavailable
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
0/9Weak
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score0/9
Profitability
- Positive ROANot passed
- Positive OCFNot passed
- Improving ΔROANot passed
- Accruals (OCF > net income)Not passed
Leverage & liquidity
- Lower debtNot passed
- Higher current ratioNot passed
- No new sharesNot passed
Efficiency
- Higher gross marginNot passed
- Higher asset turnoverNot passed
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Forensic signals
Anomaly and structural signals observed in the financial statements.
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Base metrics
- Operating margin
- -51%
- Interest coverage
- -17.6x
- Return on equity (ROE)
- -29.3%
Operating margin −5pp
Operating lossInterest coverageBase -17.6x adverse case -19.3x
Return on equity (ROE)Base -29.3% adverse case -34%
Revenue −15%
Interest coverage riskInterest coverageBase -17.6x adverse case -15x
Return on equity (ROE)Base -29.3% adverse case -26.7%
Interest rate +2pp
Interest coverage riskInterest coverageBase -17.6x adverse case -11.8x
Return on equity (ROE)Base -29.3% adverse case -31.9%
Interest coverage limit
Already below the limit by 53.9ppInterest coverage limit at an operating margin of 2.9%
Interest expense coverage threshold
Key suppliers · Annual report
Annual reportDART · 2026-03-18Suppliers disclosed by the company in its 2026-03-18 annual report.
Suppliers without disclosed amount
당사에서GMP
Who held it · filings
Filed recordA historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.
US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.
5%+ major-holding disclosures
- 지요셉26.16%2026-08-20 · 증감 -0.49%p
- 윈베스트벤처투자14.13%2025-12-10 · 증감 -1.09%p
Connections
AI-extracted related companies · for reference
Competitors
Same theme
Recent filings
HEM Pharma's latest filings on Korea's DART. Open a headline for a reference summary and the original.
Source: DART (Korea electronic disclosure)
About HEM Pharma
- What technical signals does HEM Pharma (376270) have?
- HEM Pharma current technical signals: no active technical signal.
- Is HEM Pharma a cup-and-handle pattern?
- No. HEM Pharma has no valid cup-and-handle signal right now.
- What are HEM Pharma's financials and valuation?
- HEM Pharma's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.
Like these rules? Backtest them.
Run this signal on this ticker in the free backtest builder — same window, no install.
Backtest this rule ↗Quantus Signal · live data · not investment advice · Privacy Policy